Chugai Pharmaceutical Roche Reports Mid-Year Results; Chugai Pharmaceutical Shares Held at 59.89%

TOKYO, Jul 23 (Pulse News Wire) – Chugai Pharmaceutical CO.,LTD. (6882.T) reported its mid-year results for the period ending June 30, 2026.

According to the report, Chugai Pharmaceutical CO.,LTD., headquartered in Basel, Switzerland, and led by CEO Thomas Schinecker, owns 59.89% of Chugai Pharmaceutical Co., Ltd.’s outstanding shares (representing 61.12% voting rights). Chugai Pharmaceutical’s performance data for the period from January 1, 2026, to June 30, 2026, is included in Roche Group's financial statements.

The complete investor update is available on the Roche Group website. For further inquiries, investors should Kaeko Miyata, via her direct line.